TransMedics Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $170.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors related to the advancements and strategic positioning of TransMedics Group’s next-generation Organ Care System (OCS) Lung. The company is progressing with a large, superiority-powered randomized controlled trial (RCT) following FDA conditional approval, which aims to demonstrate the effectiveness of the OCS Lung in improving outcomes for lung transplants. This study targets over 450 donor lungs and focuses on key endpoints such as freedom from primary graft dysfunction and 30-day survival rates.
Jennings believes that the next-gen OCS Lung has the potential to redefine the standard of care by addressing the limitations of existing non-portable, non-blood-based systems, which have shown inconsistent results. By generating robust clinical evidence, TransMedics aims to challenge the traditional cold storage method, which lacks prospective validation. If the clinical outcomes align with the promising preclinical data, the OCS Lung could significantly enhance organ transport and perfusion capabilities, thereby transforming market perceptions and expanding its adoption in transplant centers.
According to TipRanks, Jennings is a 2-star analyst with an average return of 0.3% and a 46.79% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Humacyte.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $145.00 price target.